	US 11,718,675 B2
	Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPalpha antibody therapy
Jie Liu, Palo Alto, CA (US); Aaron Michael Ring, New Haven, CT (US); Jens-Peter Volkmer, Menlo Park, CA (US); and Irving L. Weissman, Stanford, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US); and FORTY SEVEN, INC., Menlo Park, CA (US)
Filed on Feb. 27, 2020, as Appl. No. 16/803,751.
Application 16/803,751 is a continuation of application No. 15/660,510, filed on Jul. 26, 2017, granted, now 10,611,842.
Claims priority of provisional application 62/370,422, filed on Aug. 3, 2016.
Prior Publication US 2020/0262918 A1, Aug. 20, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/283 (2013.01) [A61K 39/0011 (2013.01); C07K 16/2803 (2013.01); C07K 16/2827 (2013.01); C07K 16/2863 (2013.01); C07K 16/2887 (2013.01); A61K 2039/507 (2013.01); A61K 2039/585 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/524 (2013.01); C07K 2317/54 (2013.01); C07K 2317/71 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

14 Claims

1. An isolated, therapeutic antibody comprising:

(i) a variable region that specifically binds to human SIRPα, comprising a light chain having all three of amino acid sequences set forth in SEQ ID NOs: 6-8, and a heavy chain having all three amino acid sequences set forth in SEQ ID NOs: 3-5;

(ii) a human Fc region comprising an amino acid substitution (a) in the CH2 region at EU index positions 234, 235, or 237; or (b) at EU index position asparagine 297, which amino acid substitution reduces binding to a human Fcγ receptor, relative to a wild-type Fc region.